HLSQ
Tessera Defense & Homeland Security Inc.
– (–)0.84USD762K成交股數22.3M市值0.0本益比(近四季)–股價營收比–營收年增(近四季)–下次財報
內部人交易 SEC Form 4 · 董事、高階主管與持股 10% 以上股東 · 交易後兩個營業日內申報
買賣點與股價近一年
統計
| 近 90 天 買進筆數 · 金額 · 人數 | 0 · 0 · 0 |
|---|---|
| 近 90 天 賣出筆數 · 金額 · 人數 | 0 · 0 · 0 |
| 其中 10b5-1 計畫賣出 | 0 筆 |
| 近 180 天 買進 · 賣出金額 | 0 · 0 |
| 近 180 天 淨額 | 0 |
公開市場買進(P)是內部人自掏腰包,通常比賣出更有資訊含量 —— 賣出的理由很多(繳稅、分散、買房),買進的理由只有一個。
10b5-1 是事先排定的交易計畫,執行時點不反映當下看法。獲配股票(A)、繳稅扣股(F)、選擇權執行(M)是薪酬流程,不是意見。
| 交易日 | 申報日 | 申報人 | 職稱 | 代碼 | 股數 | 價格 | 金額 | 交易後持股 | 原件 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-17 | 03-18 | Yeganeh Reuven | Director,TenPercentOwner | C 轉換 | 530K | 2.00 | 1.1M | 530K | SEC |
| 2026-03-17 | 03-18 | Yeganeh Reuven | Director,TenPercentOwner | S 公開市場賣出 | 530K | 5.00 | 2.7M | 0 | SEC |
| 2026-03-16 | 03-18 | Yeganeh Reuven | Director,TenPercentOwner | S 公開市場賣出 | 450K | 5.00 | 2.3M | 0 | SEC |
| 2026-03-16 | 03-18 | Yeganeh Reuven | Director,TenPercentOwner | C 轉換 | 450K | 2.00 | 900K | 450K | SEC |
| 2026-03-13 | 03-13 | Yeganeh Reuven | Director,TenPercentOwner | C 轉換 | 370K | 2.00 | 740K | 370K | SEC |
| 2026-03-13 | 03-13 | Yeganeh Reuven | Director,TenPercentOwner | S 公開市場賣出 | 370K | 5.00 | 1.9M | 0 | SEC |
| 2026-03-12 | 03-13 | Yeganeh Reuven | Director,TenPercentOwner | S 公開市場賣出 | 300K | 5.00 | 1.5M | 0 | SEC |
| 2026-03-11 | 03-13 | Yeganeh Reuven | Director,TenPercentOwner | C 轉換 | 300K | 2.00 | 600K | 30.0K | SEC |
| 2025-04-14 | 04-21 | Solomon Jonathan Eitan | Chief Executive Officer | A 獲配股票 | 127K | – | – | 127K | SEC |
| 2025-04-14 | 04-21 | Bassan Merav | Chief Development Officer | A 獲配股票 | 79.6K | – | – | 79.6K | SEC |
| 2025-04-14 | 04-21 | Wolfson Marina | Chief Financial Officer | A 獲配股票 | 68.5K | – | – | 68.5K | SEC |
| 2025-04-14 | 04-18 | Bassan Merav | Chief Development Officer | A 獲配股票 | 79.6K | – | – | 79.6K | SEC |
| 2025-04-14 | 04-18 | Wolfson Marina | Chief Financial Officer | A 獲配股票 | 68.5K | – | – | 68.5K | SEC |
| 2025-04-14 | 04-18 | Solomon Jonathan Eitan | Chief Executive Officer | A 獲配股票 | 127K | – | – | 127K | SEC |
| 2025-02-27 | 03-03 | Deerfield Private Design Fund V, L.P. | Director,Other | M 選擇權執行 | 353K | 0.93 | 329K | 1.2M | SEC |
| 2025-02-27 | 03-03 | Deerfield Mgmt V, L.P. | Director,Other | M 選擇權執行 | 353K | 0.93 | 329K | 1.2M | SEC |
| 2025-02-27 | 03-03 | Deerfield Healthcare Innovations Fund II, L.P. | Director,Other | M 選擇權執行 | 353K | 0.93 | 329K | 1.2M | SEC |
| 2025-02-27 | 03-03 | Deerfield Mgmt V, L.P. | Director,Other | M 選擇權執行 | 353K | 0.93 | 329K | 1.2M | SEC |
| 2025-02-27 | 03-03 | Deerfield Private Design Fund V, L.P. | Director,Other | M 選擇權執行 | 353K | 0.93 | 329K | 1.2M | SEC |
| 2025-02-27 | 03-03 | Deerfield Healthcare Innovations Fund II, L.P. | Director,Other | M 選擇權執行 | 353K | 0.93 | 329K | 1.2M | SEC |
| 2025-02-27 | 03-03 | Flynn James E | Director,Other | M 選擇權執行 | 353K | 0.93 | 329K | 1.2M | SEC |
| 2025-02-27 | 03-03 | Deerfield Mgmt HIF, L.P. | Director,Other | M 選擇權執行 | 353K | 0.93 | 329K | 1.2M | SEC |
| 2025-02-27 | 03-03 | Deerfield Mgmt HIF, L.P. | Director,Other | M 選擇權執行 | 353K | 0.93 | 329K | 1.2M | SEC |
| 2025-02-27 | 03-03 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Director,Other | M 選擇權執行 | 353K | 0.93 | 329K | 1.2M | SEC |
| 2025-02-27 | 03-03 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Director,Other | M 選擇權執行 | 353K | 0.93 | 329K | 1.2M | SEC |
| 2025-02-27 | 03-03 | Flynn James E | Director,Other | M 選擇權執行 | 353K | 0.93 | 329K | 1.2M | SEC |
| 2024-09-16 | 09-18 | Bassan Merav | Chief Development Officer | A 獲配股票 | 31.7K | – | – | 31.7K | SEC |
| 2024-09-16 | 09-18 | Oron Assaf | Chief Business Officer | A 獲配股票 | 25.8K | – | – | 25.8K | SEC |
| 2024-09-16 | 09-18 | Solomon Jonathan Eitan | Chief Executive Officer | A 獲配股票 | 50.6K | – | – | 53.1K | SEC |
| 2024-07-15 | 03-04 | Cystic Fibrosis Foundation | TenPercentOwner | C 轉換 | 855K | – | – | 1.8M | SEC |
| 2024-07-15 | 07-17 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Director,Other | M 選擇權執行 | 5.9M | – | – | 8.9M | SEC |
| 2024-07-15 | 07-17 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Director,Other | M 選擇權執行 | 5.9M | – | – | 8.9M | SEC |
| 2024-07-15 | 07-17 | Deerfield Mgmt V, L.P. | Director,Other | M 選擇權執行 | 5.9M | – | – | 8.9M | SEC |
| 2024-07-15 | 07-17 | Deerfield Mgmt V, L.P. | Director,Other | M 選擇權執行 | 5.9M | – | – | 8.9M | SEC |
| 2024-07-15 | 07-17 | Deerfield Private Design Fund V, L.P. | Director,Other | M 選擇權執行 | 5.9M | – | – | 8.9M | SEC |
| 2024-07-15 | 07-17 | Deerfield Healthcare Innovations Fund II, L.P. | Director,Other | M 選擇權執行 | 5.9M | – | – | 8.9M | SEC |
| 2024-07-15 | 07-17 | Deerfield Private Design Fund V, L.P. | Director,Other | M 選擇權執行 | 5.9M | – | – | 8.9M | SEC |
| 2024-07-15 | 07-17 | Deerfield Mgmt HIF, L.P. | Director,Other | M 選擇權執行 | 5.9M | – | – | 8.9M | SEC |
| 2024-07-15 | 07-17 | Deerfield Healthcare Innovations Fund II, L.P. | Director,Other | M 選擇權執行 | 5.9M | – | – | 8.9M | SEC |
| 2024-07-15 | 07-17 | Deerfield Mgmt HIF, L.P. | Director,Other | M 選擇權執行 | 5.9M | – | – | 8.9M | SEC |
| 2024-07-15 | 07-17 | Flynn James E | Director,Other | M 選擇權執行 | 5.9M | – | – | 8.9M | SEC |
| 2024-07-15 | 07-17 | Flynn James E | Director,Other | M 選擇權執行 | 5.9M | – | – | 8.9M | SEC |
| 2024-05-15 | 05-20 | GORDON CARL L | TenPercentOwner | X 選擇權履約 | 9.3M | 0.24 | 2.2M | 13.8M | SEC |
| 2024-05-15 | 05-20 | OrbiMed Israel BioFund GP Limited Partnership | TenPercentOwner | S 公開市場賣出 | 24.3K | 0.38 | 9K | 13.8M | SEC |
| 2024-05-15 | 05-20 | Chimovits Erez | TenPercentOwner | S 公開市場賣出 | 24.3K | 0.38 | 9K | 13.8M | SEC |
| 2024-05-15 | 05-20 | Chimovits Erez | TenPercentOwner | X 選擇權履約 | 9.3M | 0.24 | 2.2M | 13.8M | SEC |
| 2024-05-15 | 05-20 | OrbiMed Israel BioFund GP Limited Partnership | TenPercentOwner | X 選擇權履約 | 9.3M | 0.24 | 2.2M | 13.8M | SEC |
| 2024-05-15 | 05-20 | OrbiMed Israel GP Ltd. | TenPercentOwner | S 公開市場賣出 | 24.3K | 0.38 | 9K | 13.8M | SEC |
| 2024-05-15 | 05-20 | OrbiMed Israel GP Ltd. | TenPercentOwner | X 選擇權履約 | 9.3M | 0.24 | 2.2M | 13.8M | SEC |
| 2024-05-15 | 05-20 | GORDON CARL L | TenPercentOwner | S 公開市場賣出 | 24.3K | 0.38 | 9K | 13.8M | SEC |
| 2024-05-15 | 05-17 | Cystic Fibrosis Foundation | TenPercentOwner | X 選擇權履約 | 4.8M | – | – | 9.3M | SEC |
| 2024-03-15 | 03-19 | Deerfield Mgmt V, L.P. | Director,TenPercentOwner,Other | A 獲配股票 | 3.1M | – | – | 3.1M | SEC |
| 2024-03-15 | 03-19 | Deerfield Private Design Fund V, L.P. | TenPercentOwner,Other | A 獲配股票 | 3.1M | – | – | 3.1M | SEC |
| 2024-03-15 | 03-19 | Deerfield Private Design Fund V, L.P. | TenPercentOwner,Other | A 獲配股票 | 3.1M | – | – | 3.1M | SEC |
| 2024-03-15 | 03-19 | Deerfield Healthcare Innovations Fund II, L.P. | Director,TenPercentOwner,Other | A 獲配股票 | 3.1M | – | – | 3.1M | SEC |
| 2024-03-15 | 03-19 | Deerfield Healthcare Innovations Fund II, L.P. | Director,TenPercentOwner,Other | A 獲配股票 | 3.1M | – | – | 3.1M | SEC |
| 2024-03-15 | 03-19 | Deerfield Mgmt HIF, L.P. | Director,TenPercentOwner,Other | A 獲配股票 | 3.1M | – | – | 3.1M | SEC |
| 2024-03-15 | 03-19 | Deerfield Mgmt HIF, L.P. | Director,TenPercentOwner,Other | A 獲配股票 | 3.1M | – | – | 3.1M | SEC |
| 2024-03-15 | 03-19 | Flynn James E | Director,TenPercentOwner,Other | A 獲配股票 | 3.1M | – | – | 3.1M | SEC |
| 2024-03-15 | 03-19 | Flynn James E | Director,TenPercentOwner,Other | A 獲配股票 | 3.1M | – | – | 3.1M | SEC |
| 2024-03-15 | 03-19 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Director,TenPercentOwner,Other | A 獲配股票 | 3.1M | – | – | 3.1M | SEC |
| 2024-03-15 | 03-19 | Deerfield Mgmt V, L.P. | Director,TenPercentOwner,Other | A 獲配股票 | 3.1M | – | – | 3.1M | SEC |
| 2024-03-15 | 03-19 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | Director,TenPercentOwner,Other | A 獲配股票 | 3.1M | – | – | 3.1M | SEC |
| 2023-11-29 | 12-01 | Oron Assaf | Chief Business Officer | S 公開市場賣出 | 5.4K | 0.40 | 2K | 5.5K | SEC |
| 2023-11-29 | 12-01 | Oron Assaf | Chief Business Officer | S 公開市場賣出 | 2.1K | 0.34 | 699.04 | 0 | SEC |
| 2023-11-29 | 12-01 | Oron Assaf | Chief Business Officer | S 公開市場賣出 | 3.4K | 0.35 | 1K | 2.1K | SEC |
| 2023-05-22 | 05-24 | Oron Assaf | Chief Business Officer | P 公開市場買進 | 3.2K | 0.27 | 861.84 | 10.9K | SEC |
| 2023-05-19 | 05-22 | Oron Assaf | Chief Business Officer | P 公開市場買進 | 6.5K | 0.28 | 2K | 7.7K | SEC |
| 2023-05-18 | 05-22 | Oron Assaf | Chief Business Officer | P 公開市場買進 | 1.2K | 0.27 | 324.27 | 1.2K | SEC |
| 2023-02-27 | 03-17 | GORDON CARL L | TenPercentOwner | P 公開市場買進 | 348K | 0.25 | 87K | 3.2M | SEC |
| 2023-02-27 | 03-17 | OrbiMed Israel GP Ltd. | TenPercentOwner | P 公開市場買進 | 348K | 0.25 | 87K | 3.2M | SEC |
| 2023-02-27 | 03-17 | Chimovits Erez | TenPercentOwner | P 公開市場買進 | 348K | 0.25 | 87K | 3.2M | SEC |
| 2023-02-27 | 03-17 | OrbiMed Israel BioFund GP Limited Partnership | TenPercentOwner | P 公開市場買進 | 348K | 0.25 | 87K | 3.2M | SEC |
| 2022-11-04 | 11-14 | Ugwumba Chidozie | Other | S 公開市場賣出 | 1.5K | 0.38 | 570.38 | 3.0M | SEC |
| 2022-11-03 | 11-14 | Ugwumba Chidozie | Other | S 公開市場賣出 | 2.0K | 0.37 | 740.00 | 3.0M | SEC |
| 2022-11-02 | 11-14 | Ugwumba Chidozie | Other | S 公開市場賣出 | 2.4K | 0.36 | 869.76 | 3.0M | SEC |
| 2022-11-01 | 11-14 | Ugwumba Chidozie | Other | S 公開市場賣出 | 1.3K | 0.36 | 468.00 | 3.0M | SEC |
| 2022-10-31 | 11-14 | Ugwumba Chidozie | Other | S 公開市場賣出 | 3.3K | 0.37 | 1K | 3.0M | SEC |
| 2022-10-28 | 11-14 | Ugwumba Chidozie | Other | S 公開市場賣出 | 1.5K | 0.36 | 549.36 | 3.0M | SEC |
| 2022-10-27 | 11-14 | Ugwumba Chidozie | Other | S 公開市場賣出 | 1.5K | 0.36 | 541.80 | 3.0M | SEC |
機構持股(13F) 管理規模 1 億美元以上的機構,每季末後 45 天內申報 ·
前 25 大持有機構季末市值 · 與前一季股數比較
| 機構 | 持股 | 季末市值 | 股數季變化 | 動作 |
|---|---|---|---|---|
| 沒有 13F 資料。 | ||||
持有機構數近 12 季
13F 只申報多頭部位(含可轉債與選擇權,選擇權這裡已排除),不申報放空,也不申報 1 億美元以下的機構。同一集團多個申報主體會各算一家。
放空餘額 FINRA 每月兩次(15 日與月底結算)·
空單佔流通股近 13 個月
最新一期
沒有放空餘額資料。
空單佔比 10% 以上算高、20% 以上算很高(這是通行的說法,不是本站的判斷)。回補天數 = 空單 ÷ 日均量,天數愈長,空方要出場時愈容易推升股價。
放空餘額是「有人借股票賣掉還沒還」的存量,不代表看空的人正在加碼;避險基金做多空配對時也會產生空單。
| 結算日 | 空單股數 | 與上期比 | 佔流通股 | 日均量 | 回補天數 |
|---|